Cargando…

Predictive Factors Related to the Efficacy of Golimumab in Patients with Rheumatoid Arthritis

In order to investigate the predictive factors related to clinical efficacy and radiographic progression at 24 weeks by looking at the serum levels of tumor necrosis factor (TNF)-α and interleukin (IL)-6 including baseline characteristics in patients with rheumatoid arthritis (RA) treated with golim...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kanbe, Katsuaki, Chiba, Junji, Inoue, Yasuo, Taguchi, Masashi, Yabuki, Akiko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Libertas Academica 2015
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4337590/ https://www.ncbi.nlm.nih.gov/pubmed/25741185 http://dx.doi.org/10.4137/CMAMD.S22155

Ejemplares similares

Simultaneous Treatment with Subcutaneous Injection of Golimumab and Intra-articular Injection of Triamcinolone Acetonide (K-Method) in Patients with Rheumatoid Arthritis Undergoing Switching of Biologics: Retrospective Case–Control Study
por: Kanbe, Katsuaki, et al.
Publicado: (2016)

Biologic-free remission by orthopaedic surgery in non-responder to infliximab for rheumatoid arthritis
por: Kanbe, Katsuaki, et al.
Publicado: (2015)

Analysis of Mitogen-Activated Protein Kinases in Bone and Cartilage of Patients with Rheumatoid Arthritis Treated with Abatacept
por: Kanbe, Katsuaki, et al.
Publicado: (2016)

Golimumab for Rheumatoid Arthritis
por: Pelechas, Eleftherios, et al.
Publicado: (2019)

Long-Term Efficacy of Rehabilitation Following Arthroscopic Synovectomy in Patients With Rheumatoid Arthritis Treated With Biologic Agents
por: Kanbe, Katsuaki, et al.
Publicado: (2017)

Effectiveness of Golimumab in Clinical Management of Patients with Rheumatoid Arthritis
por: Shono, Eisuke
Publicado: (2013)

A Randomized Phase IIb Study of Mavrilimumab and Golimumab in Rheumatoid Arthritis
por: Weinblatt, Michael E., et al.
Publicado: (2017)

Long-term Use of Golimumab in Daily Practice for Patients with Rheumatoid Arthritis
por: Nemoto, Tetsuya, et al.
Publicado: (2020)

Effectiveness and Safety of Golimumab for Patients ≥75 Years Old with Rheumatoid Arthritis
por: Kurosawa, Yoichi, et al.
Publicado: (2022)

Long-term effectiveness and safety of infliximab, golimumab and golimumab-IV in rheumatoid arthritis patients from a Canadian prospective observational registry
por: Rahman, Proton, et al.
Publicado: (2020)

The Effectiveness of Intravenous Golimumab Administered Directly After Infliximab in Rheumatoid Arthritis Patients
por: Bray, Vance J., et al.
Publicado: (2018)

Erratum for Long-term Use of Golimumab in Daily Practice for Patients with Rheumatoid Arthritis
por: Nemoto, Tetsuya, et al.
Publicado: (2021)

Opsonic and Antibody Responses to Pneumococcal Polysaccharide in Rheumatoid Arthritis Patients Receiving Golimumab Plus Methotrexate
por: Migita, Kiyoshi, et al.
Publicado: (2015)

Efficacy of Switching from Infliximab to Subcutaneous Golimumab in Patients with Rheumatoid Arthritis to Control Disease Activity or Adverse Events
por: Wakabayashi, Hiroki, et al.
Publicado: (2016)

Successful Switch to Golimumab for Eosinophilia and Skin Symptoms Related to Multiple Biologics in a Patient with Rheumatoid Arthritis
por: Azuma, Naoto, et al.
Publicado: (2017)

Golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis: results of the GO-FORTH study
por: Tanaka, Yoshiya, et al.
Publicado: (2011)

Efficacy and Safety of Subcutaneous Golimumab in Methotrexate‐Naive Patients With Rheumatoid Arthritis: Five‐Year Results of a Randomized Clinical Trial
por: Emery, Paul, et al.
Publicado: (2016)

Efficacy and safety of intravenous golimumab plus methotrexate in patients with rheumatoid arthritis aged < 65 years and those ≥ 65 years of age
por: Tesser, John, et al.
Publicado: (2019)

Will savings from biosimilars offset increased costs related to dose escalation? A comparison of infliximab and golimumab for rheumatoid arthritis
por: Curtis, Jeffrey R., et al.
Publicado: (2019)

Dose Adjustment of Methotrexate Administered Concomitantly with Golimumab for Rheumatoid Arthritis in Japanese Real-World Clinical Settings
por: Yamairi, Fumiko, et al.
Publicado: (2020)

Persistence and Safety of Golimumab in Elderly Patients with Rheumatoid Arthritis and Renal Dysfunction in a Real-World Setting
por: Yokoyama, Seiji, et al.
Publicado: (2022)

Successful adalimumab graded challenge after allergic delayed reaction to golimumab in a woman with rheumatoid arthritis
por: Rivolta, Federica, et al.
Publicado: (2023)

Prediction of remission and low disease activity in disease-modifying anti-rheumatic drug-refractory patients with rheumatoid arthritis treated with golimumab
por: Vastesaeger, Nathan, et al.
Publicado: (2016)

Golimumab: A novel human anti-TNF-α monoclonal antibody for the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis
por: Kay, Jonathan, et al.
Publicado: (2010)

Pooled safety results across phase 3 randomized trials of intravenous golimumab in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis
por: Husni, M. Elaine, et al.
Publicado: (2022)

Efficacy and Safety of Intravenous Golimumab Through One Year in Patients With Active Psoriatic Arthritis
por: Husni, M. Elaine, et al.
Publicado: (2020)

Satisfaction with Subcutaneous Golimumab and its Auto-Injector among Rheumatoid Arthritis Patients with Inadequate Response to Adalimumab or Etanercept
por: Dehoratius, Raphael J., et al.
Publicado: (2018)

Two-year clinical outcomes after discontinuation of long-term golimumab therapy in Korean patients with rheumatoid arthritis
por: Shin, Kichul, et al.
Publicado: (2022)

Effectiveness and safety of intravenous golimumab with and without concomitant methotrexate in patients with rheumatoid arthritis in the prospective, noninterventional AWARE study
por: Broadwell, Aaron, et al.
Publicado: (2023)

Patient-reported outcomes with golimumab in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: non-interventional study GO-NICE in Germany
por: Krüger, Klaus, et al.
Publicado: (2018)

Safety and clinical efficacy of golimumab in the treatment of arthritides
por: Simsek, Ismail, et al.
Publicado: (2010)

Golimumab for Polyarticular Juvenile Idiopathic Arthritis and Psoriatic Arthritis: Pharmacologic and Clinical Considerations
por: McIntosh, Sydney Moore, et al.
Publicado: (2023)

Golimumab for the treatment of refractory juvenile idiopathic arthritis-associated uveitis
por: William, Mridula, et al.
Publicado: (2012)

Golimumab in juvenile idiopathic arthritis-associated uveitis unresponsive to Adalimumab
por: Lanz, Sofia, et al.
Publicado: (2021)

Effect of Golimumab Dose Escalation in Japanese Patients With Rheumatoid Arthritis: Post-Hoc Analysis of Post-Marketing Surveillance Data
por: Shimizu, Hirohito, et al.
Publicado: (2020)

Persistence with golimumab in immune-mediated rheumatic diseases: a systematic review of real-world evidence in rheumatoid arthritis, axial spondyloarthritis, and psoriatic arthritis
por: Svedbom, Axel, et al.
Publicado: (2017)

Assessment by MRI of inflammation and damage in rheumatoid arthritis patients with methotrexate inadequate response receiving golimumab: results of the GO-FORWARD trial
por: Conaghan, Philip G, et al.
Publicado: (2011)

Correction to: Effect of Golimumab Dose Escalation in Japanese Patients With Rheumatoid Arthritis: Post-Hoc Analysis of Post-Marketing Surveillance Data
por: Shimizu, Hirohito, et al.
Publicado: (2020)

Incidence of Infusion Reactions and Clinical Effectiveness of Intravenous Golimumab Versus Infliximab in Patients with Rheumatoid Arthritis: The Real-World AWARE Study
por: Curtis, Jeffrey R., et al.
Publicado: (2021)

A Real-World Claims Database Study Assessing Long-Term Persistence with Golimumab Treatment in Patients with Rheumatoid Arthritis in Japan
por: Miyashiro, Masahiko, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_6c61bdd0iinckh845smc43oqcm